Lurasidone Hydrochloride Tablet Market - Global Forecast 2026-2032

List of Tables

The Lurasidone Hydrochloride Tablet Market is projected to grow by USD 1.75 billion at a CAGR of 7.01% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.09 billion
Estimated Year [2026]	USD 1.15 billion
Forecast Year [2032]	USD 1.75 billion
CAGR (%)	7.01%

Lurasidone Hydrochloride Tablets: Executive Overview

Lurasidone hydrochloride tablets are an oral atypical antipsychotic used primarily in the treatment of schizophrenia and depressive episodes associated with bipolar I disorder, subject to local regulatory approvals. The market is shaped by clinical positioning, prescribing guidance, reimbursement access, generic availability, tolerability considerations, and the quality of psychiatric care delivery. Demand is also influenced by diagnosis rates, continuity of treatment, patient adherence, and the availability of specialist services.

Clinical Practice and Access Are Reshaping the Landscape

The landscape is shifting toward more individualized psychiatric treatment, with clinicians weighing symptom profile, adverse-effect risks, comorbidities, medication interactions, and patient preferences. Greater attention to metabolic health and long-term safety supports interest in therapies with differentiated tolerability characteristics, while generic competition and formulary management place sustained pressure on procurement and pricing. Digital prescribing, integrated behavioral-health models, and improved post-market safety monitoring are also changing how treatment is initiated and maintained.

Artificial Intelligence Supports Safer, More Personalized Use

Artificial intelligence can assist the lurasidone hydrochloride tablet ecosystem through clinical decision support, identification of treatment-response patterns, adherence-risk detection, pharmacovigilance signal prioritization, and demand planning. Natural-language systems may help organize clinical documentation and patient-reported outcomes, while predictive tools can flag patients who may require follow-up. These applications require representative data, transparent validation, human clinical oversight, privacy safeguards, and controls against algorithmic bias; AI should support rather than replace prescribing judgment.

Regional Differences Reflect Regulation, Care Capacity, and Reimbursement

North America is characterized by established psychiatric-care infrastructure, payer scrutiny, and strong attention to formulary placement and generic substitution. Latin America presents a mixed environment in which public and private access, national procurement, and specialist availability vary considerably. Europe combines harmonized regulatory structures with country-level reimbursement decisions and differing approaches to generic dispensing. The Middle East shows uneven access linked to healthcare investment, specialist concentration, and national pharmaceutical policies. Africa faces substantial gaps in diagnosis, continuity of care, and medicine availability, although public-health strengthening can improve access. Asia-Pacific is highly diverse, spanning advanced health systems with mature psychiatric services and rapidly developing markets where affordability, distribution, and workforce capacity remain central concerns.

Economic and Security Alliances Shape Procurement and Standards

ASEAN markets generally require locally adapted access strategies because regulatory pathways, reimbursement systems, and healthcare capacity differ among member states. BRICS economies combine large and varied patient populations with distinct procurement practices, domestic-manufacturing priorities, and regulatory requirements. The European Union benefits from coordinated scientific and regulatory frameworks, while national pricing and reimbursement decisions remain important. G7 countries typically emphasize evidence-based prescribing, pharmacovigilance, and budget oversight. GCC states often combine centralized purchasing with investment in specialist healthcare infrastructure. NATO members span diverse health systems, but shared attention to medicine security, supply resilience, and continuity of essential treatment is strategically relevant.

Country-Level Priorities Vary Across Established and Emerging Systems

Australia emphasizes regulated prescribing, public reimbursement considerations, and specialist mental-health access. Brazil combines public-system procurement with private coverage and regional disparities. Canada's decentralized reimbursement environment makes provincial formulary decisions important. China is shaped by centralized regulatory oversight, hospital procurement, and expanding mental-health services. France, Germany, Italy, and Spain operate within European regulatory principles while applying distinct national reimbursement and prescribing practices. India faces major variation in affordability, specialist availability, and urban-rural access. Japan has an established medical system with close attention to safety, reimbursement, and prescribing practice. Mexico's access differs between public institutions and private providers. Russia's environment is influenced by national regulation, procurement, and supply considerations. South Korea combines advanced healthcare delivery with structured reimbursement and regulatory oversight. The United Kingdom relies on national clinical guidance and health-service formulary processes, while the United States is strongly influenced by payer coverage, pharmacy benefits, prescribing practice, and generic substitution.

Priorities for Leaders in Access, Evidence, and Treatment Continuity

Industry leaders should align evidence generation with approved indications, clinically meaningful outcomes, and real-world treatment needs, while maintaining rigorous safety surveillance. Access strategies should account for public procurement, private reimbursement, generic competition, and country-specific regulatory requirements rather than relying on a single global model. Patient-support initiatives can focus on adherence, education, early recognition of adverse effects, and coordination between psychiatric and primary care. Supply planning should include qualified alternative sources, quality controls, and transparent shortage-response procedures. AI investments should begin with clearly defined use cases, validated data, explainability, cybersecurity, and ongoing clinical governance.

Methodology: Evidence-Based Synthesis of the Tablet Market

This executive summary uses the supplied market scope-lurasidone hydrochloride tablets-and organizes findings across clinical use, regulation, reimbursement, healthcare delivery, technology, and geographic context. The analysis is qualitative and avoids unsupported estimates, market sizing, forecasts, market shares, and company-specific claims. Regional, group, and country observations are framed as structural considerations and should be validated against current regulatory labels, treatment guidelines, reimbursement schedules, procurement rules, epidemiological evidence, and pharmacovigilance sources before operational decisions are made.

Conclusion: Sustainable Access Depends on Evidence and Health-System Fit

The lurasidone hydrochloride tablet landscape is defined by the interaction of clinical differentiation, patient-centered care, affordability, generic competition, regulatory oversight, and treatment continuity. Regional and national conditions vary substantially, making localized access planning essential. Leaders who combine robust safety evidence, responsible stewardship, resilient supply, practical adherence support, and carefully governed digital tools will be better positioned to support appropriate use across diverse healthcare systems.

Product Code: MRR-9C4233EE5E34

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Lurasidone Hydrochloride Tablet Market, by Indication

7.1. Introduction
7.2. Bipolar Depression
7.3. Schizophrenia

8. Lurasidone Hydrochloride Tablet Market, by Dosage Strength

8.1. Introduction
8.2. 20 Mg
8.3. 40 Mg
8.4. 60 Mg
8.5. 80 Mg

9. Lurasidone Hydrochloride Tablet Market, by Product Type

9.1. Introduction
9.2. Branded
9.3. Generic

10. Lurasidone Hydrochloride Tablet Market, by Formulation

10.1. Introduction
10.2. Film Coated Tablet
10.3. Orally Disintegrating Tablet

11. Lurasidone Hydrochloride Tablet Market, by End User

11.1. Introduction
11.2. Adult Patient
11.3. Geriatric Patient
11.4. Pediatric Patient

12. Lurasidone Hydrochloride Tablet Market, by Distribution Channel

12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy

13. Lurasidone Hydrochloride Tablet Market, by Region

13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa

14. Lurasidone Hydrochloride Tablet Market, by Group

14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO

15. Lurasidone Hydrochloride Tablet Market, by Country

15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
- 16.2.1. Concentration Ratio (CR)
- 16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025

17. Company Profiles

17.1. AbbVie Inc
17.2. Accord Healthcare Inc
17.3. Astellas Pharma Inc
17.4. Aurobindo Pharma Limited
17.5. Bristol-Myers Squibb Company
17.6. Dr Reddy's Laboratories Limited
17.7. Gedeon Richter Plc
17.8. H Lundbeck A/S
17.9. Hikma Pharmaceuticals PLC
17.10. Intas Pharmaceuticals Limited
17.11. Lupin Limited
17.12. Macleods Pharmaceuticals Limited
17.13. Mylan NV (now part of Viatris Inc)
17.14. Otsuka Pharmaceutical Co Ltd
17.15. Pfizer Inc
17.16. Sandoz Group AG
17.17. Sumitomo Pharma Co Ltd
17.18. Sun Pharmaceutical Industries Limited
17.19. Sunovion Pharmaceuticals Inc
17.20. Taj Pharma Limited
17.21. Teva Pharmaceutical Industries Limited
17.22. Torrent Pharmaceuticals Limited
17.23. Zydus Cadila Healthcare Limited

18. Key Experts